Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Precigen (NASDAQ:PGEN) with a Buy and raises the price targ...
Precigen (NASDAQ:PGEN) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $(0.10) by...
Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to ...
The credit facility provides Precigen with up to $125 million committed across two tranches, subject to the terms and condition...
